Diagnostic techniques and prognostic indicators

Whole-Body MR Imaging: The Novel, “Intrinsically Hybrid,” Approach to Metastases, Myeloma, Lymphoma, in Bones and Beyond. Lecouvet FE et al. PET Clin. 2018 Oct. doi: 10.1016/j.cpet.2018.05.006. [Epub 2018 Aug 17] Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosis. Leiba M et al. Oral Dis. 2018 Oct. doi: 10.1111/odi.12901.…

Details

Current treatments

Determining treatment intensity in elderly patients with multiple myeloma. Salvini M et al. Expert Rev Anticancer Ther. 2018 Sep. doi: 10.1080/14737140.2018.1496823. [Epub 2018 Jul 13] Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat. Chari A et al. Future Oncol. 2018 Sep. doi: 10.2217/fon-2017-0727. [Epub 2018 May 30] Autologous stem cell transplantation in first…

Details

General

The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets. Abramson HN. Clin Lymphoma Myeloma Leuk. 2018 Sep. doi: 10.1016/j.clml.2018.06.015. [Epub 2018 Jun 18] A new conceptual framework for the therapy by optimized multidimensional pulses of therapeutic activity. The case of multiple myeloma model. Horvath D and Brutovsky B. J Theor Biol. 2018 Oct 7. doi: 10.1016/j.jtbi.2018.06.015. [Epub 2018 Jun…

Details

Biology and genetics

Bortezomib Targets Sp Transcription Factors in Cancer Cells. Karki Ket al. Mol Pharmacol. 2018 Oct. doi: 10.1124/mol.118.112797. [Epub 2018 Aug 16] IRF4 in multiple myeloma-Biology, disease and therapeutic target. Agnarelli A et al. Leuk Res. 2018 Sep. doi: 10.1016/j.leukres.2018.07.025. [Epub 2018 Aug 3] PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism. Zhang H et al. Mol Oncol. 2018 Sep.…

Details

Emerging treatments

Ixazomib: a novel drug for multiple myeloma. Zanwar S et al. Expert Rev Hematol. 2018 Sep 1. doi: 10.1080/17474086.2018.1518129. [Epub ahead of print] A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. San-Miguel JF et al. Haematologica. 2018 Sep. doi: 10.3324/haematol.2017.185991. [Epub 2018 Jun 28] Phase I study…

Details

Complications of myeloma and its treatments

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Cella D et al. Ann Hematol. 2018 Sep 4. doi: 10.1007/s00277-018-3469-4. [Epub ahead of print] Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma. Lee AC et al. J…

Details

Emerging treatments

Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal. Armoiry X et al. Pharmacoeconomics. 2018 Sep. doi: 10.1007/s40273-018-0644-3. Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. Sivik JM et al. Support Care Cancer. 2018 Sep. doi: 10.1007/s00520-018-4165-6. Surgical thyroparathyroidectomy…

Details

Diagnostic techniques and prognostic indicators

The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma. Jiang Yet al. Oncol Lett. 2018 Sep. doi: 10.3892/ol.2018.9128. [Epub 2018 Jul 11] Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Stolzenburg A et al. Eur J Nucl Med Mol Imaging. 2018 Sep. doi: 10.1007/s00259-018-3997-0. Determining treatment intensity…

Details